STOCK TITAN

Landos Biopharma Inc - LABP STOCK NEWS

Welcome to our dedicated news page for Landos Biopharma (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Landos Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Landos Biopharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Landos Biopharma Inc

Nasdaq:LABP

LABP Rankings

LABP Stock Data

67.13M
1.32M
9.92%
48.96%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Blacksburg

About LABP

there is an unmet need for new treatments for autoimmune diseases that transform paradigms and clinical practice. landos will address that unmet clinical need. we know physicians are tired of settling for mediocre therapies for patients living with autoimmune disorders. with one first in class, oral therapy for inflammatory bowel disease (ibd) and its two clinical manifestations: crohn’s disease and ulcerative colitis, showing remarkable preclinical results and entering clinical trials, our team is poised to soon offer ibd patients a better way. the bottom line is this: patients deserve treatment options that are safer, more effective, and less disruptive to their lives. that is what drives landos scientists and our team each and every day.